Accessibility Menu
ResMed logo

ResMed(OTC) RSMDF

Market Cap$32.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+723%
5 Year-10%
1 Year+37%
1 Month+34%
$22.48
+0.00%
+0.00Today
ResMed last closing stock price
MetricPriceDate
Last closeUSD 22.482026-08-13
ResMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+34.45%USD 16.722026-07-28
1 month+34.45%USD 16.722026-07-13
3 month+26.58%USD 17.762026-05-15
Year to date-15.34%USD 26.552025-12-30
1 year+36.89%USD 16.422025-08-12
3 year+32.49%USD 16.972023-08-11
5 year-10.33%USD 25.072021-08-13
Since inception+722.72%USD 2.732011-10-26

ResMed Financials at a Glance

Market Cap

$32.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.65B

Net Income (TTM)

$1.52B

EPS (TTM)

$1.04

P/E Ratio

21.55

Dividend

$0.24

Beta (Volatility)

-0.90 (Low)

Price

$22.48

Volume

100

Open

$22.48

Previous Close

$22.48

Daily Range

$22.48 - $22.48

52-Week Range

$11.85 - $37.91

Estimated Earnings Date

Oct 22, 2026

RSMDF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ResMed

ResMed Inc. is a leading global medical technology company specializing in the development, manufacturing, and distribution of medical devices and digital health solutions for the healthcare sector. The company operates primarily in two segments: Sleep and Respiratory Care, and Software as a Service (SaaS).

Products and Services
  • Comprehensive range of products for respiratory disorders
  • Cloud-based informatics software for improved patient outcomes
  • Out-of-hospital software solutions for healthcare providers
Growth Outlook
  • Revenue of $1.43 billion in Q3 2026, showing consistent growth
  • Operating income margin of 34.9% indicates strong operational efficiency
  • Net income of $398 million reflects robust profitability
Financial Highlights
  • Trailing twelve months (TTM) revenue of $5.56 billion
  • Net profit margin of 27.4% demonstrates effective cost management
  • Cash flow from operations of $554 million in Q3 2026 supports liquidity
ResMed Inc. has established itself as a key player in the medical technology industry, focusing on innovative solutions for sleep and respiratory care. The company's diverse product offerings cater to a wide range of healthcare needs, enhancing patient outcomes through advanced technology. The growth outlook remains positive, with significant revenue generation and strong operating margins indicating a solid business model. Recent financial performance highlights a healthy net profit margin and substantial cash flow, underscoring the company's financial stability and operational efficiency. This combination of innovation, growth potential, and financial strength positions ResMed Inc. as an attractive option for investors interested in the healthcare sector.
AI Generated • Jul 31, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

11,370

CEO

Mick Farrell, MBA

Website

www.resmed.com

Headquarters

San Diego, CA 92123, US

RSMDF Financials

Key Financial Metrics (TTM)

Gross Margin

61.16%

Operating Margin

33.48%

Net Income Margin

26.94%

Return on Equity

23.88%

Return on Capital

25.54%

Return on Assets

16.99%

Earnings Yield

4.64%

Dividend Yield

1.07%

Payout Ratio

40.19%

Stock Overview

Market Cap

$32.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.45B

Volume

100

Avg. Volume

4.99K

Financials (TTM)

Gross Profit

$3.46B

Operating Income

$1.89B

EBITDA

$2.15B

Operating Cash Flow

$3.16B

Capital Expenditure

-$267.46M

Free Cash Flow

$2.89B

Cash & ST Invst.

$1.47B

Total Debt

$825.92M

ResMed Performance Analysis

ResMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30USD 4,222,995,27918.0%
20242024-06-30USD 4,685,297,52810.9%
20252025-06-30USD 5,146,329,1189.8%
20262026-06-30USD 5,653,446,3419.9%
ResMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-0.9%
Q22025-12-316.5%
Q32026-03-310.6%
Q42026-06-302.3%
ResMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30USD 0.6114.8%
20242024-06-30USD 0.6913.7%
20252025-06-30USD 0.9537.4%
20262026-06-30USD 1.049.7%
ResMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-09-30-8.1%
Q22025-12-3113.1%
Q32026-03-311.1%
Q42026-06-30-2.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

$1.46B

+8.6%

Gross Profit

$861.22M

+5.0%

Gross Margin

58.84%

N/A

Market Cap

$32.61BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$3.08M

N/A

Employees

10,600

N/A

Net Income

$383.43M

+1.0%

EBITDA

$492.96M

-7.4%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

$1.47B

+21.5%

Total Debt

$825.92M

-3.0%

Accounts Receivable

$1.04B

+4.6%

Inventory

$945.81M

+2.0%

Long Term Debt

$536.83M

-33.8%

Short Term Debt

$289.09M

+615.5%

Return on Assets

16.99%

N/A

Return on Invested Capital

25.00%

N/A

Free Cash Flow

$1.65B

+224.6%

Operating Cash Flow

$1.81B

+235.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
FSNUFFresenius SE & Co. KGaA
$54.35+0.00%
DSKYFDaiichi Sankyo Company, Limited
$16.41+0.00%
TRUMFTerumo Corporation
$17.01+24.25%
TRUMYTerumo Corporation
$16.67+1.83%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About RSMDF

What is the current price of ResMed?

ResMed is trading at $22.48 per share.

What is the 52-week range for ResMed?

Over the past 52 weeks, ResMed has traded between $11.85 and $37.91.

How much debt does ResMed have?

As of the most recent reporting period, ResMed reported total debt of $825.92M.

How much cash does ResMed have on hand?

ResMed reported $1.47B in cash and cash equivalents in its most recent financial results.

What is ResMed’s dividend yield?

ResMed currently has a dividend yield of 1.07%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services